BriaCell Therapeutics Corp. (BCT.TO)
CAD 5.92
(-1.33%)
CAD 5.92
(-1.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -23.27 Million USD | -52.22% |
| 2022 | -15.28 Million USD | -514.36% |
| 2021 | 3.68 Million USD | 166.5% |
| 2020 | 1.38 Million CAD | 46.29% |
| 2019 | 946.42 Thousand CAD | 124.78% |
| 2018 | -3.81 Million CAD | -47.92% |
| 2017 | -2.58 Million CAD | -54.91% |
| 2016 | -1.66 Million CAD | -15.71% |
| 2015 | -1.44 Million CAD | -229.42% |
| 2014 | -437.27 Thousand CAD | -3.07% |
| 2013 | -424.25 Thousand CAD | 64.6% |
| 2012 | -1.19 Million CAD | -13.79% |
| 2011 | -1.05 Million CAD | -224.5% |
| 2010 | -324.56 Thousand CAD | -38.78% |
| 2009 | -233.87 Thousand CAD | -104.93% |
| 2008 | -114.12 Thousand CAD | 11.57% |
| 2007 | -129.05 Thousand CAD | -1404.03% |
| 2006 | -8580.77 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -9.22 Million USD | 6.1% |
| 2024 Q1 | -8.5 Million USD | -10.35% |
| 2024 Q2 | -9.82 Million USD | -15.6% |
| 2024 Q4 | -5.76 Million USD | 37.51% |
| 2023 Q4 | -7.7 Million USD | -35.74% |
| 2023 FY | -23.27 Million USD | -52.22% |
| 2023 Q3 | -5.67 Million USD | -280.24% |
| 2023 Q2 | 3.14 Million USD | 158.29% |
| 2023 Q1 | -5.4 Million USD | -27.86% |
| 2022 Q2 | -3.93 Million USD | -72.11% |
| 2022 Q4 | -4.22 Million USD | -283.56% |
| 2022 FY | -15.28 Million USD | -514.36% |
| 2022 Q3 | 2.3 Million USD | 158.55% |
| 2022 Q1 | -2.28 Million USD | -43.44% |
| 2021 Q3 | -4.8 Million CAD | -1658.67% |
| 2021 FY | 3.68 Million USD | 166.5% |
| 2021 Q1 | -350.75 Thousand CAD | 43.9% |
| 2021 Q4 | -1.59 Million USD | 66.88% |
| 2021 Q2 | -273.48 Thousand CAD | 22.03% |
| 2020 Q4 | -625.19 Thousand CAD | -24.69% |
| 2020 Q3 | -501.4 Thousand CAD | 64.73% |
| 2020 Q2 | -1.42 Million CAD | -21.09% |
| 2020 Q1 | -1.17 Million CAD | 14.81% |
| 2020 FY | 1.38 Million CAD | 46.29% |
| 2019 Q1 | -980.12 Thousand CAD | 32.0% |
| 2019 Q3 | -1.06 Million CAD | 21.51% |
| 2019 Q2 | -1.36 Million CAD | -38.89% |
| 2019 Q4 | -1.37 Million CAD | -28.97% |
| 2019 FY | 946.42 Thousand CAD | 124.78% |
| 2018 Q2 | -802.04 Thousand CAD | -59.44% |
| 2018 FY | -3.81 Million CAD | -47.92% |
| 2018 Q4 | -1.44 Million CAD | -29.92% |
| 2018 Q3 | -1.1 Million CAD | -38.32% |
| 2018 Q1 | -503.02 Thousand CAD | 53.24% |
| 2017 Q1 | -325.02 Thousand CAD | -58.06% |
| 2017 Q4 | -1.07 Million CAD | -24.79% |
| 2017 Q3 | -862.09 Thousand CAD | -155.0% |
| 2017 FY | -2.58 Million CAD | -54.91% |
| 2017 Q2 | -338.08 Thousand CAD | -4.02% |
| 2016 Q3 | -272.51 Thousand CAD | 64.85% |
| 2016 Q2 | -775.31 Thousand CAD | -148.13% |
| 2016 Q1 | -312.45 Thousand CAD | -4.48% |
| 2016 Q4 | -205.62 Thousand CAD | 24.54% |
| 2016 FY | -1.66 Million CAD | -15.71% |
| 2015 Q1 | -119.18 Thousand CAD | 32.03% |
| 2015 Q4 | -299.06 Thousand CAD | 22.56% |
| 2015 Q2 | -664.89 Thousand CAD | -457.88% |
| 2015 FY | -1.44 Million CAD | -229.42% |
| 2015 Q3 | -386.21 Thousand CAD | 41.91% |
| 2014 Q3 | -99.92 Thousand CAD | -20.24% |
| 2014 Q2 | -83.1 Thousand CAD | 0.72% |
| 2014 Q1 | -83.7 Thousand CAD | 9.33% |
| 2014 FY | -437.27 Thousand CAD | -3.07% |
| 2014 Q4 | -175.35 Thousand CAD | -75.49% |
| 2013 Q3 | -118.92 Thousand CAD | -9.22% |
| 2013 FY | -424.25 Thousand CAD | 64.6% |
| 2013 Q1 | -106.42 Thousand CAD | 86.29% |
| 2013 Q4 | -92.32 Thousand CAD | 22.37% |
| 2013 Q2 | -108.88 Thousand CAD | -2.31% |
| 2012 Q3 | -125.72 Thousand CAD | 11.3% |
| 2012 Q2 | -141.74 Thousand CAD | 5.41% |
| 2012 Q1 | -149.84 Thousand CAD | 70.36% |
| 2012 FY | -1.19 Million CAD | -13.79% |
| 2012 Q4 | -776.09 Thousand CAD | -517.3% |
| 2011 Q3 | -235.27 Thousand CAD | -27.21% |
| 2011 Q1 | -107.81 Thousand CAD | -491.48% |
| 2011 Q2 | -184.95 Thousand CAD | -71.55% |
| 2011 Q4 | -505.6 Thousand CAD | -114.9% |
| 2011 FY | -1.05 Million CAD | -224.5% |
| 2010 Q3 | -189.63 Thousand CAD | -103.96% |
| 2010 Q2 | -92.97 Thousand CAD | -63.05% |
| 2010 Q1 | -57.02 Thousand CAD | 59.41% |
| 2010 FY | -324.56 Thousand CAD | -38.78% |
| 2010 Q4 | 27.54 Thousand CAD | 114.52% |
| 2009 Q3 | -8929.93 CAD | 73.8% |
| 2009 Q4 | -140.48 Thousand CAD | -1473.14% |
| 2009 Q1 | -52.16 Thousand CAD | 7.93% |
| 2009 FY | -233.87 Thousand CAD | -104.93% |
| 2009 Q2 | -34.08 Thousand CAD | 34.65% |
| 2008 Q1 | -10.3 Thousand CAD | 73.83% |
| 2008 Q3 | -28.32 Thousand CAD | -45.0% |
| 2008 Q4 | -56.66 Thousand CAD | -100.06% |
| 2008 FY | -114.12 Thousand CAD | 11.57% |
| 2008 Q2 | -19.53 Thousand CAD | -89.61% |
| 2007 Q3 | -12.99 Thousand CAD | 71.07% |
| 2007 FY | -129.05 Thousand CAD | -1404.03% |
| 2007 Q4 | -39.36 Thousand CAD | -202.89% |
| 2007 Q2 | -44.91 Thousand CAD | -57.64% |
| 2007 Q1 | -28.49 Thousand CAD | 0.0% |
| 2006 FY | -8580.77 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -189.09% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 36.926% |
| Helix BioPharma Corp. | -9.37 Million CAD | -148.343% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -750.46% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | -18.356% |
| Satellos Bioscience Inc. | -15.46 Million CAD | -50.503% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 31.129% |
| Sernova Corp. | -41.13 Million CAD | 43.419% |